UTRS - Minerva Surgical, Inc. Stock Price, Fair Value and News

Market Closed

UTRS Stock Valuation Analysis

Valuation

Max Portfolio %

UTRS Price Action

UTRS RSI Chart

UTRS Stock Valuation Analysis

Valuation

Max Portfolio %

UTRS Valuation

UTRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

UTRS Fundamentals

UTRS Revenue

UTRS Earnings

UTRS Profitability

UTRS Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	51.9M	52.3M	51.7M	0
2022	51.2M	50.1M	50.1M	50.3M
2021	41.4M	44.9M	48.5M	52.1M
2020	0	0	0	37.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Minerva Surgical, Inc.

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

CEO	Mr. Todd Usen
WEBSITE	https://minervasurgical.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	174